CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 397 filers reported holding CRISPR THERAPEUTICS AG in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $635 | -19.2% | 14,000 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $786 | +39.1% | 14,000 | +12.0% | 0.00% | +33.3% |
| Q1 2023 | $565 | +11.2% | 12,500 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $508 | -99.9% | 12,500 | +27.6% | 0.00% | -25.0% |
| Q3 2022 | $640,000 | +7.4% | 9,800 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $596,000 | -6.0% | 9,800 | -3.0% | 0.00% | 0.0% |
| Q1 2022 | $634,000 | -17.1% | 10,100 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $765,000 | -32.3% | 10,100 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $1,130,000 | -31.6% | 10,100 | -1.0% | 0.01% | -33.3% |
| Q2 2021 | $1,651,000 | +52.3% | 10,200 | +14.6% | 0.01% | +50.0% |
| Q1 2021 | $1,084,000 | -20.5% | 8,900 | 0.0% | 0.01% | -25.0% |
| Q4 2020 | $1,363,000 | +44.2% | 8,900 | -21.2% | 0.01% | +14.3% |
| Q3 2020 | $945,000 | +114.3% | 11,300 | +88.3% | 0.01% | +250.0% |
| Q2 2020 | $441,000 | – | 6,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |